Optiscan Filed FDA Applications for Surgery Devices

The company has submitted its InVue and InForm devices for federal regulatory review in the United States.

Updated on Oct. 4, 2026 in Cancer

Bold flat-color editorial illustration of two precision medical devices, symbolizing the regulatory review of new surgical and pathology technology. — Optiscan has filed 510(k) applications with the U.S. FDA for its InVue surgical tool and InForm digital pathology system to seek federal regulatory approval. AI Illustration. Upload story photo >

Live Poll

Do you trust that new medical imaging technologies generally lead to better patient outcomes?

Optiscan has lodged 510(k) applications with the U.S. FDA for its InVue precision surgery tool and its InForm digital pathology device. These technologies are designed to provide surgeons with real-time, cellular-level imaging during medical procedures.

Why it matters

The devices aim to enhance surgical accuracy by allowing real-time tissue visualization at the cellular level. This could significantly impact the annual market for cancer surgery, which serves millions of patients across the United States.

Approximately 60% of cancer patients in the United States, representing millions of individuals, undergo surgery for their disease annually. The intraoperative imaging market is currently projected to grow to US$1.55 billion by 2030.

The players

Optiscan

An imaging technology company that specializes in the development of real-time, microscopic digital pathology and surgical tools.

U.S. Food and Drug Administration

The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices through rigorous regulatory review.

The details

The InVue device, first unveiled in June 2024, is engineered to assist surgeons by providing high-resolution, real-time cellular images during operations. The FDA review process will now evaluate the technical, performance, and clinical evidence submitted by Optiscan for both the InVue and InForm systems.

Optiscan unveiled the InVue device in June 2024.
The InForm digital pathology device was submitted for FDA review on October 2, 2026.

Cancer
Sept. 30
FDA Granted Fast Track Status to Prostate Cancer Program
Biotech
Sept. 30
Imagion Biosystems Secured Phase 2 Trial Approval
Asthma
Sept. 28
Diagnos Submitted CARA System Request to FDA

The Big Picture

This submission follows the established FDA 510(k) regulatory pathway, which serves as the primary gateway for introducing new medical technologies into the clinical environment. The move reflects a broader trend of integrating high-resolution digital imaging into standard surgical practices.

If approved, these devices could improve the precision of cancer surgeries, potentially leading to better surgical outcomes for the millions of patients treated annually. The technology aims to provide doctors with better tools during operations without requiring changes to standard patient recovery routines.

The takeaway

Advancements in intraoperative imaging are increasingly focusing on real-time cellular visualization to assist surgical teams during complex procedures. These tools represent a shift toward high-tech surgical support that may eventually become standard in oncology departments.